Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
Giulio Metro(University of Perugia), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Marcella Mottolese, Lucia Stocchi(Ospedale Infermi di Rimini), Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), Michelangelo Russillo(National Cancer Institute), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Jennifer Foglietta(Ospedale Santa Maria), Antonello Vidiri
Cited by 168
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398